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Abstract
Introduction Signal transducers and activators of transcription
(STATs) are mediators of cytokine and growth factor signaling.
In recent years, STAT5b has emerged as a key regulator of
tumorigenesis. STAT5b phosphorylation and activation is
mediated by several kinases known to be overexpressed in
breast cancer, such as epidermal growth factor receptor, HER2,
and c-Src. Breast tumor kinase (Brk), also known as protein
tyrosine kinase 6, is a nonreceptor tyrosine kinase expressed in
more than 60% of breast cancers. Only a few substrates of the
Brk tyrosine kinase have been identified, the most recent being
STAT3. In the present article we investigate the potential role of
Brk in the phosphorylation and activation STAT5b.
Methods To determine whether Brk can phosphorylate
STAT5b, transient transfection and in vitro kinase assays were
performed. Luciferase reporter assays were used to measure
Brk-induced STAT5b transcriptional activity. siRNA technology
was utilized to investigate the biological significance of Brk-
induced activation of STAT5b in breast cancer cell models.
Results Phosphospecific antibodies, mutational analysis, and in
vitro kinase assays demonstrated that Brk specifically mediated
STAT5b phosphorylation at the activating tyrosine, Y699.
Transient transfection of Brk into the Brk-negative BT-549
breast cancer cell line enhanced STAT5b transcriptional activity,
as measured by a STAT5-specific luciferase reporter.
Furthermore, overexpression of kinase active c-Src enhanced
Brk-induced STAT5b transcriptional activity. In Brk-positive
breast cancer cell lines BT-20 and SKBr3, knockdown of Brk
protein or of STAT5b protein using siRNA methodology resulted
in a decrease in DNA synthesis. Knockdown of Brk and STAT5b
together did not further decrease DNA synthesis compared with
each alone, suggesting that Brk and STAT5b converge on the
same pathway, ultimately leading to cellular proliferation.
Conclusion Our studies demonstrate that Brk phosphorylates
STAT5b on Y699, leading to increased STAT5b transcriptional
activity. Furthermore, analysis of DNA synthesis suggests that
STAT5b and Brk are converging upon the same proproliferative
signaling pathway in breast cancer cells. We propose that Brk,
like other tyrosine kinases, signals downstream to STAT5b to
mediate proliferation of breast cancer cells. These results further
establish STAT5b as well as Brk as potential targets for breast
cancer therapy.
Introduction
As mediators of cytokine-induced and growth factor-induced
gene expression, signal transducers and activators of tran-
scription (STATs) are involved in cellular differentiation, prolif-
eration, and survival. Upon cytokine or growth factor binding to
its receptor, the latent cytoplasmic STAT proteins are
recruited to the receptor complex resulting in STAT activation
by either receptor tyrosine kinases or nonreceptor tyrosine
kinases such as Janus kinases or c-Src. Activation of STAT
proteins requires phosphorylation on a conserved tyrosine res-
idue located in the carboxy terminus. Phosphorylation of this
tyrosine leads to phosphotyrosine–Src homology domain 2-
mediated reciprocal dimerization. The activated STAT dimer
then translocates to the nucleus and binds to a STAT consen-
sus DNA element, resulting in gene transcription. The STAT
family consists of seven members that can be divided into twoPage 1 of 10
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STAT4, STAT6), and those that respond to cytokine and
growth factor signals (STAT1, STAT3, STAT5a, STAT5b) [1-
3].
Although STAT5a and STAT5b play a fundamental role in nor-
mal growth and development of the mammary gland, both pro-
teins are overexpressed or constitutively activated in cancers,
including some breast cancer tumors [4-9]. Owing to their
ability to regulate the expression of genes involved in cell-cycle
regulation (cyclin D1, c-myc, and p21) and cellular survival
(Bcl-XL), STAT5a and STAT5b have emerged as possible tar-
gets for cancer therapeutics [10]. Recent evidence indicates
that STAT5b, but not STAT5a, has a proproliferative role in
breast cancer, head and neck cancer, and prostate cancer
[11-14]. Since STAT5b mediates breast cancer proliferation,
identification of kinases that increase STAT5b activity is criti-
cal to identifying potential therapeutic targets.
Breast tumor kinase (Brk) is a nonreceptor tyrosine kinase
originally isolated from an involved axillary node of a patient
with metastatic breast cancer, and is expressed in more than
60% of breast cancers [15,16]. With 46% amino acid identity
to c-Src, Brk is distantly related to the Src family of tyrosine
kinases [17,18]. Although normally expressed in the gastroin-
testinal tract, expression of Brk is not detected in the normal
mammary gland [16,19]. Stable transfection of Brk in the
immortalized nontransformed human mammary cell lines HB4a
and MCF10A, however, leads to sensitization to epidermal
growth factor and results in a partially transformed phenotype
[20]. Brk also enhances epidermal growth factor-induced
ErbB3 and Akt phosphorylation in the HB4a cells [21]. Fur-
thermore, knockdown of the Brk protein decreases prolifera-
tion of breast cancer cell lines [22]. Given its role in breast
cancer cell proliferation, survival, and tumorigenesis, identifica-
tion of the substrates of this tyrosine kinase is of utmost
importance.
Although STAT5b is involved in cancer proliferation, mutations
of STAT5b to account for this increased biological activity
have not been identified. Alternatively, increased STAT5b acti-
vation results from the overexpression and/or the constitutive
activation of tyrosine kinases, such as the epidermal growth
factor receptor (EGFR), c-Src, and the fusion protein Bcr/Abl
[4,6]. Since all identified Brk substrates are also substrates for
c-Src, we examined the ability of Brk to mediate STAT5b phos-
phorylation, a known c-Src substrate.
In the studies presented here, the ability of Brk to phosphor-
ylate and activate STAT5b and the biological significance of
this activation were investigated. Exogenous expression of Brk
and STAT5b demonstrated that Brk mediates the phosphor-
ylation of the activating tyrosine, Y699. Furthermore, an in vitro
kinase assay determined that Brk can directly phosphorylate
STAT5b on Y699. Subsequently, this Brk-mediated STAT5b
phosphorylation leads to STAT5b transcriptional activity, and
this activity is further increased by kinase active c-Src. The
results of siRNA experiments suggest that Brk and STAT5b
are in the same signaling pathway, which ultimately leads to
the proliferation of breast cancer cells. These studies further
support targeting STAT5b as a potential breast cancer
therapeutic.
Materials and methods
Cell lines and transient transfections
The human breast cancer cell lines SKBr3, BT-20, BT-549,
MDA-MB-468, and T47D were obtained from the American
Type Culture Collection (Manassas, VA, USA). Cells were
maintained in DMEM plus 10% FCS and were passaged twice
per week. Mouse embryo fibroblasts (MEF5-/-) from STAT5a/b
knockout mice (provided by Dr J Ihle, St Jude Children's Hos-
pital, Memphis, TN, USA) were passaged twice per week and
maintained in DMEM plus 10% FCS. Cells were transfected
with STAT constructs [23], Brk constructs (generous gift from
Dr C Lange, University of Minnesota, Minneapolis, MN, USA),
and c-Src constructs as previously described [24], using Lipo-
fectAMINE and PLUS reagent according to the manufac-
turer's instructions (Invitrogen, Gaithersburg, MD, USA).
Reagents
The polyclonal STAT5a-specific and STAT5b-specific anti-
bodies were developed in our laboratory, as previously
described [23]. Polyclonal anti-STAT3 antibodies, polyclonal
anti-Brk antibodies, and monoclonal antiphosphotyrosine anti-
bodies (PY-99) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The monoclonal anti-β-actin antibody
was from Sigma (St Louis, MO, USA). The antiphospho-
STAT5a/b (Y694/Y699) antibody was developed in conjunc-
tion with Aves Labs (Tigand, OR, USA) as described else-
where (EM Fox, T Bernaciak, J Wen, A Weaver, M Shupnik,
CM Silva - unpublished data). The protease inhibitor cocktail
was from Calbiochem (San Diego, CA, USA). The acrylamide
was obtained from Bio-Rad (Hercules, CA, USA), and the
prestained molecular weight marker was from Invitrogen.
Except as noted, other reagents were of either reagent grade
or molecular biological grade from Sigma.
Immunoprecipitations and immunoblotting
Cells were lysed in 150 mM NaCl, 5 mM ethylenediamine
tetraacetic acid, 1% Triton X-100, 1% deoxycholate, 50 mM
Tris (pH 7.4), containing protease inhibitors and phosphatase
inhibitors. Lysates were incubated with the indicated antibody
overnight at 4°C, and protein A-agarose (Santa Cruz Biotech-
nology) was added for an additional 1 hour at 4°C. Agarose
pellets were washed three times in detergent lysis buffer, and
the bound proteins were removed by boiling in 1 × Laemmli
buffer. Proteins were separated on polyacrylamide gels and
were analyzed as previously described [12].Page 2 of 10
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MEF5-/- and BT-549 cells were transfected with the Spi2.1-
containing luciferase reporter plasmid. Forty-eight hours post
transfection, lysates were prepared and luciferase activity was
measured [24]. The luciferase values (arbitrary units), as
measured by a Berthold Luminometer (Berthold, Oak Ridge,
TN, USA), were normalized to total protein.
Recombinant protein
STAT5b or Y699F cDNA was cloned into the pGEX4T-1 plas-
mid (Amersham, Piscataway, NJ, USA) using the EcoRI and
NotI restriction sites. The GST, GST-STAT5b, and GST-
Y699F plasmids were generated and transformed into
Escherichia coli BL21. Protein expression was induced by 1
mM isopropyl-beta-D-thiogalactopyranoside (IPTG in Luria
broth (LB) broth at 18°C for 18 hours. Bacterial cells were
lysed in 1 × PBS containing 1 mM ethylenediamine tetraacetic
acid, 5 mM dithiothreitol, 1.5% sarkosyl, 1% Triton, 2 mM phe-
nylmethylsulfonyl fluoride (PMSF), and 1 μg/ml pepstatin fol-
lowed by sonication. GST, GST-wtSTAT5b, and GST-Y699F
were isolated using glutathione agarose beads (Sigma) follow-
ing the manufacturer's instructions. Following elution with
excess glutathione (50 mM Tris–HCl/10 mM glutathione, pH
8.0), the recombinant proteins were dialyzed in 1 × Tris-buff-
ered saline/10% glycerol. Protein concentration was deter-
mined by the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA,
USA).
In vitro kinase assay
Purified recombinant Brk (Upstate, Billerica, MA, USA) and
purified recombinant GST, GST-STAT5b, or GST-Y699F
were incubated with 20 nM ATP in reaction buffer (100 mM
Tris–HCl, pH 7.4, 125 mM MgCl2, 25 mM MnCl2, 2 mM eth-
ylene glycol tetraacetic acid (EGTA), 0.25 mM NaVO4, 2 mM
dithiothreitol) at 30°C for 30 minutes. An equal volume of 2 ×
Laemmli was added to end the reaction. Phosphorylation of
STAT5b was analyzed by immunoblotting with our specific
phospho-Y694/Y699 STAT5a/b antibody.
RNA isolation and reverse transcriptase polymerase 
chain reaction
Total RNA was isolated from the breast cancer cell lines using
the RNeasy mini kit (Qiagen, Valencia, CA, USA) following the
manufacturer's instructions. The cDNA was generated using
iScript cDNA synthesis (Bio-Rad). The cDNA was amplified
using primers for Brk or β-actin as described by Kasprzycka
and colleagues [25].
Small interfering RNA methodology
Knockdown of Brk and/or STAT5b was performed using the
siGenome SMARTpool duplex (Dharmacon, Lafayette, CO,
USA) transfected with Oligofectamine (Invitrogen) according
to the manufacturer's instructions.
DNA synthesis assay
Following 48 hours of transfection with siRNA, SKBr3 cells or
BT-20 cells were serum starved for an additional 18 hours and
were then incubated with 100 μM bromodeoxyuridine (BrdU)
for 6 hours. Cells were fixed and permeabilized as previously
described [12]. Cells were blocked in 20% goat serum/PBS
for 20 minutes at 37°C, and then were incubated with anti-
BrdU-Alexa-Fluor 594 (Molecular Probes, Carlsbad, CA, USA)
for 1 hour at 37°C. BrdU incorporation was visualized using a
Leica DM RBE Fluorescence microscope (model RS232C;
Leica Microsystems, Bannockburn, IL, USA).
Results
STAT tyrosine phosphorylation mediated by breast 
tumor kinase
Previous studies have demonstrated that STAT5a and
STAT5b are tyrosine phosphorylated by the EGFR and c-Src
kinases, two kinases that are involved in breast cancer
[12,26,27]. Given the recent evidence that Brk phosphor-
ylates STAT3 [1], we investigated whether this kinase could
also mediate the phosphorylation of the related STAT5a and
STAT5b proteins. Mouse embryo fibroblasts from STAT5a/b
knockout mice (MEF5-/-) were transfected with STAT3,
STAT5a, or STAT5b along with various Brk expression vec-
tors. MEF5-/- cells were chosen because these cells do not
express endogenous Brk (Figure 1), STAT5a, or STAT5b.
Immunoprecipitations were performed for the transfected
STAT using specific antibodies and were analyzed for tyrosine
phosphorylation by immunoblotting. Additionally, total lysates
were analyzed for the expression of the Brk constructs.
In agreement with previous findings, Figure 1a demonstrates
that wildtype Brk and constitutively active Brk (Y447F) were
able to mediate STAT3 tyrosine phosphorylation, while the
kinase inactive Brk (K219M) or vector (pRc) demonstrated no
detectable tyrosine phosphorylation [1]. Importantly, Brk and
the Y447F Brk, but not the K219M Brk, were also able to
mediate STAT5a and STAT5b tyrosine phosphorylation (Fig-
ure 1b,c). These data demonstrate for the first time that Brk
mediates tyrosine phosphorylation of STAT5a and STAT5b in
addition to STAT3. Since our previous studies demonstrated
that STAT5b, but not STAT5a, elicits a proproliferative effect
in breast cancer cells [12], and other studies have shown that
Brk also increases proliferation of breast cancer cells [22], we
focused our efforts on Brk-mediated activation of STAT5b.
Phosphorylation of STAT5b by breast tumor kinase
While phosphorylation of Y699 is required for transcriptional
activity, three tyrosines located in the transactivation domain
can also be phosphorylated and modulate STAT5b activity
[23]. These tyrosines are either positive (Y725) or negative
(Y740 and Y743) regulators of STAT5b activity, and their
phosphorylations are mediated by c-Src (Y699 and Y725) and
the EGFR (Y699, Y725, Y740, and Y743) [12,27]. We inves-
tigated the ability of Brk to phosphorylate each of the four iden-Page 3 of 10
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tyrosine, Y699. MEF5-/- cells were transfected with STAT5b
along with Brk constructs, and STAT5b immunoprecipitations
were analyzed using the antiphospho-Y699 STAT5b-specific
antibody.
Both Brk and Y447F Brk were able to mediate the phosphor-
ylation of Y699, while it was not detectable in vector cells or
K219M Brk-transfected cells (Figure 2a). To determine
whether Brk mediates the phosphorylation of tyrosines other
than Y699, MEF5-/- cells were transfected with Brk along with
STAT5b mutants in which all but one of the four tyrosines was
mutated. Brk induced detectable tyrosine phosphorylation of
wildtype STAT5b and the Y725/740/743F mutant (with intact
Y699), confirming the results with the antiphospho-Y699-spe-
cific antibody. None of the other STAT5b mutant constructs,
however, were phosphorylated by Brk (Figure 2b). These
results demonstrate that Brk primarily mediates Y699 phos-
phorylation on STAT5b and not the three transactivation
domain tyrosines.
Breast tumor kinase mediates STAT5b transcriptional 
activity
Since Y699 phosphorylation is required for the transcriptional
function of STAT5b, we analyzed the ability of Brk to mediate
STAT5b transcriptional activity. MEF5-/- cells were transfected
with the STAT5-specific luciferase reporter plasmid (Spi2.1-
luc) along with His-vector, STAT5b, or Y699F plus or minus
Brk. Since the MEF5-/- cells express endogenous STAT1 and
STAT3, the specificity of this reporter was demonstrated by
the inability of the His-vector to mediate luciferase activity (Fig-
ure 2c). The expression of STAT5b increased Spi2.1-medi-
ated luciferase activity, and the cotransfection of Brk
significantly increased this transcriptional activity further. As
seen previously, the Y699F STAT5b mutant was unable to
mediate STAT5b transcriptional activity, and the addition of
Brk had no effect. These results demonstrate not only that Brk
mediates STAT5b transcriptional activity, but that Y699 is
required.
Breast tumor kinase directly phosphorylates Y699 of 
STAT5b in vitro
To determine whether Brk could mediate the phosphorylation
and activation of STAT5b directly, or whether other tyrosine
kinases known to activate STAT5b (such as EGFR and c-Src)
were required, an in vitro kinase assay was performed. Purified
recombinant Brk was incubated with purified recombinant
GST, GST-STAT5b, or GST-Y699F. The in vitro kinase reac-
tion was analyzed via silver stain (Figure 3a) and by immunob-
lotting with the antiphospho-Y699 STAT5b-specific antibody
(Figure 3b). The silver stain illustrates that GST, GST-STAT5b,
GST-Y699F, and Brk were all expressed (Figure 3a). Further-
more, the specificity of the phospho-Y699 STAT5b antibody
was confirmed by its inability to recognize the recombinant
GST-Y699F protein (Figure 3b). Phospho-Y699 STAT5b anti-
body, however, detected phosphorylated Brk in this assay.
Immunoblotting with this antibody demonstrated that the GST-
STAT5b was phosphorylated on Y699 in the presence of, but
not in the absence of, Brk. This result demonstrates that Brk is
able to directly phosphorylate Y699 on STAT5b in vitro.
Breast tumor kinase expression in human breast cancer 
cell lines
While studies in the MEF5-/- cells allowed us to characterize
the role of Brk in STAT5b activation, we continued our studies
in breast cancer cell lines as a means to investigate the biolog-
ical relevance of Brk-mediated STAT5b activation. We deter-
mined the relative expression of Brk by analyzing mRNA and
protein levels in a panel of frequently studied breast cancer
cell lines. The total mRNA was isolated from each cell line,
cDNA was generated, and primers specific for either Brk or β-
actin were used for amplification [25]. In each sample, the rel-
ative expression of Brk mRNA was determined by normalizing
to the amount of β-actin. The expression of Brk mRNA in the
Figure 1
Breast tumor kinase mediates tyrosine phosphorylation of signal transducers and activators of transcriptioni l ti  f i l tr r   activators of transcription. Breast tumor kinase (Brk) mediates tyro-
sine phosphorylation of signal transducer and activator of transcription (STAT)3, STAT5a, and STAT5b. STAT5a/b knockout mouse embryo fibro-
blast (MEF5-/-) cells were transfected with (a) STAT3, (b) STAT5a, or (c) STAT5b along with either pRc (vector), Brk, K219M Brk (kinase inactive), 
or Y477F Brk (constitutively active). Immunoprecipitations (IPs) for STAT3, STAT5a, or STAT5b were performed using antibodies specifically 
directed against each STAT and were analyzed by immunoblotting with antibodies directed toward STAT3, STAT5a, STAT5b (middle), or phospho-
tyrosine (top). Total lysates were analyzed for the expression of the Brk construct by immunoblotting with anti-Brk antibody (bottom).Page 4 of 10
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cell line expressed the lowest detectable amount of Brk
mRNA. While BT-20 cells and T47D cells had the highest
mRNA levels, SKBr3 cells and MDA-MB-468 cells expressed
moderate levels, and BT-549 cells had no detectable Brk
mRNA.
The amount of Brk protein in detergent cell lysates from each
cell line was determined by immunoblotting. The relative
expression of Brk protein was determined by normalizing to
the nuclear import protein Ran, shown previously as a valid
normalization control in breast cancer cell lines [28]. Again the
amount of Brk protein in the MDA-MB-468 cell line was set to
1 (Figure 4b) because this cell line had the lowest detectable
amount of Brk protein. Brk was highly expressed in BT-20 cells
and T47D cells, was moderately expressed in SKBr3 cells and
MDA-MB-468 cells, and was not detectable in BT-549 cells.
Relatively high levels of Brk expression were seen in both the
estrogen-receptor-positive T47D cells and the estrogen-
receptor-negative BT-20 cells. Furthermore, while MDA-MB-
468 cells, BT-20 cells, and BT-549 cells all express the EGFR,
they expressed different amounts of Brk.
Breast tumor kinase mediates STAT5b activity in breast 
cancer cells
To examine the ability of Brk to mediate the transcriptional
activity of endogenous STAT5b in a breast cancer cell line, the
BT-549 cells, which have no detectable endogenous Brk,
were utilized. The STAT5-specific Spi2.1 luciferase reporter
with or without Brk was transfected into the BT-549 cells.
While there was a detectable basal level of transcriptional
activity, Brk significantly increased endogenous STAT5b tran-
scriptional activity, as did the constitutively active Brk (Y447F)
(Figure 5a). Although not nearly as effective, the kinase inac-
Figure 2
Signal transducer and activator of transcription 5b tyrosine phosphorylation and transcriptional activation. (a) Mouse embryo fibroblast (MEF5-/-) 
cells were transfected with signal transducer and activator of transcription 5b (STAT5b) along with pRc (vector), breast tumor kinase (Brk), K219M, 
or Y447F. Immunoprecipitations (IPs) were performed using antibodies specifically against STAT5b and were analyzed by immunoblotting with anti-
bodies directed toward phospho-Y699 STAT5b (top) or STAT5b (bottom). (b) MEF5-/- cells were transfected with various STAT5b constructs along 
with constitutively active Y447F Brk. Immunoprecipitations (IPs) were performed as above and were analyzed via immunoblotting with antiphospho-
tyrosine antibody (top) or anti-STAT5b antibody (bottom). (c) MEF5-/- were transfected with the STAT5-specific Spi2.1 promoter luciferase construct 
and either His-vector, His-STAT5b, or His-Y699F with or without Brk. Luciferase activity was measured and normalized to total protein. Values from 
four independent experiments performed in triplicate reported as the fold induction over His, pRc ± standard error: His, pRc (1.00 ± 0.00) and Brk 
(1.05 ± 0.39); STAT5b, pRc (28.89 ± 5.51) and Brk (75.48 ± 25.79); Y699F, pRc (1.17 ± 0.14) and Brk (0.93 ± 0.27). Student's t test was used 
to determine statistical significance between STAT5b pRc and STAT5b Brk. *P = 0.0123.Page 5 of 10
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ferase activity compared with vector alone. This result is not
necessarily unexpected since a role of the kinase inactive Brk
in other cell models has been reported (see Discussion).
Since Brk and c-Src are both able to phosphorylate STAT5b
on Y699, the potential cooperation between Brk and c-Src
was investigated. As previously, Brk dramatically enhanced
STAT5b transcriptional activity, and the K219M Brk was also
able to significantly enhance this activity (Figure 5b). Unex-
pectedly, exogenous overexpression of c-Src did not enhance
STAT5b transcriptional activity (Figure 5b). c-Src overexpres-
sion enhanced Brk-induced STAT5b transcriptional activity,
however, indicating that Brk and c-Src together can enhance
STAT5b transcriptional activity. The kinase activity of Brk was
necessary for this collaboration as the addition of c-Src to
K219M Brk did not enhance STAT5b activity. Likewise, the
kinase inactive c-Src (K-Src) failed to significantly enhance
Brk-induced STAT5b transcriptional activity, suggesting that
the kinase activity of c-Src is also necessary for this coopera-
tion between Brk and c-Src. While Brk and c-Src individually
have different effects on STAT5b transcriptional activity, these
two tyrosine kinases together increase STAT5b transcriptional
activity. These data suggest that Brk and c-Src do not merely
substitute for one another in activating STAT5b, but rather that
Brk can function independently as well as together with c-Src.
STAT5b and breast tumor kinase involvement in DNA 
synthesis
To determine the biological significance of the Brk-mediated
increase in STAT5b activity, the role of Brk and STAT5b, indi-
vidually and together, on DNA synthesis in breast cancer cell
lines was investigated. Since Brk signals downstream of the
EGFR [20,21,30,30] and HER2 [29] tyrosine kinases, the
EGFR/HER2-overexpressing SKBr3 breast cancer cell line
and the EGFR-overexpressing BT-20 breast cancer cell line
were chosen for these studies. Both cell lines express the c-
Src and Brk tyrosine kinases as well as STAT5b. To investi-
gate the effect on proliferation, siRNA technology was used to
knockdown Brk or STAT5b protein levels, individually or
together, and then the effect on DNA synthesis was measured
by BrdU incorporation. Lysates were analyzed via immunoblot-
ting to determine significant and specific knockdown of Brk
and STAT5b.
As shown in Figure 6a,c, knockdown of Brk did not effect the
expression of STAT5b and knockdown of STAT5b did not
Figure 3
In vitro Y699 phosphorylation by breast tumor kinase orylation by breast tumor kinase. In vitro Y699 
phosphorylation of signal transducer and activator of transcription 5b 
(STAT5b) by breast tumor kinase (Brk). Purified recombinant GST, 
GST-STAT5b, or GST-Y699F were incubated with (+) or without (-) 
purified recombinant Brk in reaction buffer containing 20 nM ATP at 
30°C for 30 minutes. An equal volume of 2 × Laemmli buffer was 
added to end the reaction and the samples were run on SDS-PAGE. 
Gels were analyzed via (a) silver stain and (b) by immunoblotting with 
an antiphospho-Y699 STAT5b-specific antibody.
Figure 4
Breast tumor kinase expression in breast cancer cell lines. (a) Total 
RNA was isolated from the breast cancer cell lines using the RNeasy kit 
(Qiagen), and the cDNA was generated using iScript cDNA synthesis 
(Bio-Rad). The cDNA was amplified using primers specifically for 
breast tumor kinase (Brk) or β-actin. The relative level of Brk mRNA was 
determined using densitometric analysis and was normalized to the 
amount of β-actin. The level of Brk mRNA in the MDA-MB-468 cell line 
was set to 1; numbers indicate the fold increase compared with the 
468 cells. (b) Whole-cell lysates were prepared from the breast cancer 
cell lines. Lysates were immunoblotted with anti-Brk antibody (top) and 
with anti-Ran antibody (bottom). The relative expression of Brk protein 
was determined using densitometric analysis and was normalized to 
the amount of Ran. The expression of Brk protein in the MDA-MB-468 
cell line was set to 1; numbers indicate the fold increase compared 
with the 468 cells.Page 6 of 10
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and/or STAT5b did not effect the expression of HER2, EGFR,
c-Src, STAT3, or STAT1 (data not shown). Knockdown of Brk
(siBrk) inhibited DNA synthesis in both SKBr3 cells and BT-20
cells by 47% and 31%, respectively (Figure 6b,d). Knockdown
of STAT5b (siSTAT5b) significantly decreased DNA synthesis
of both cell lines to an extent similar to that seen with Brk
knockdown. Importantly, the knockdown of Brk and STAT5b
together did not further decrease DNA synthesis compared
with either single knockdown, suggesting that signaling medi-
ated by Brk and STAT5b are contributing to the same propro-
liferative pathway.
Discussion
Although traditionally known for its role in growth hormone sig-
naling and mammary gland development, STAT5b has
emerged as a therapeutic target due to its pivotal role in can-
cer. Inhibition of STAT5b, but not of STAT5a, in xenograft
models of head and neck carcinomas via antisense oligonucle-
otides repressed tumor growth and hindered expression of the
STAT5-regulated genes cyclin D1 and Bcl-XL [13,14]. STAT5b
is more abundantly expressed than STAT5a in prostate cancer
and breast cancer cell lines [12,31]. Inhibition of STAT5b via
dominant-negative constructs and siRNA technology
decreases DNA synthesis (Figure 6) [32], while exogenous
expression of a basally active STAT5b mutant (Y740/743F)
increases DNA synthesis of breast cancer cells [12].
Together, these data establish a fundamental role for STAT5b
in the process of breast cancer tumorigenesis.
Since activating mutations in STAT5b have not been found in
breast cancer, it is important to look upstream to identify the
kinases that regulate STAT5b, thus potentially leading to its
increased activity in breast cancer cells. Both STAT5b and
STAT3 are activated by several kinases overexpressed in
breast cancer, including the EGFR, HER2, and c-Src. STAT3
was recently shown to also be phosphorylated by the nonre-
ceptor tyrosine kinase Brk [1]. Since Brk is expressed in more
than 60% of breast tumors but not in normal mammary tissue,
it has been suggested to be a potential therapeutic target for
breast cancer. Since evidence supports the involvement of
both Brk and STAT5b in breast cancer proliferation, we inves-
tigated the ability of Brk to phosphorylate STAT5b and the bio-
logical significance of this activation.
Using synthetic peptides containing consensus motifs for the
EGFR, insulin receptor, c-Src, or Abl tyrosine kinases, it was
determined that the c-Src-preferred synthetic peptide is the
best Brk substrate [17]. Given these data, it is not surprising
that all of the identified Brk substrates (Sam68, SLM-1, SLM-
2, STAP-2, paxillin, STAT3) are also c-Src substrates
[1,30,33-35]. We have identified two more Brk substrates,
STAT5a and STAT5b, which are also c-Src substrates (Figure
1). c-Src can mediate the phosphorylation of Y699 and Y725,
however, Brk mediates Y699 phosphorylation but not Y725
Figure 5
Breast tumor kinase mediates endogenous signal transducer and acti-vator of transcription 5b tran cripti nal activity
vator of transcription 5b transcriptional activity. (a) BT-549 cells were 
transfected with the Spi2.1 promoter luciferase construct along with 
pRc, breast tumor kinase (Brk), K219M, or Y447F expression vectors. 
Luciferase activity was measured and normalized to total protein. Val-
ues from four independent experiments carried out in triplicate were 
reported as average luciferase/protein ± standard error: pRc (1,859.37 
± 592.24); Brk (10,031.94 ± 1,359.68); K219M (3,109.82 ± 777.57), 
Y477F (12,878.57 ± 2,464.26). Student's t test was used to deter-
mine statistical significance between pRc and Brk, and between pRc 
and K219M. *P < 0.0001, • P = 0.0430. (b) BT-549 cells were trans-
fected with the Spi2.1 promoter luciferase construct along with pRc, 
Brk, or K219M, and either pcDNA, c-Src, or K-Src expression vectors. 
Luciferase activity was measured and normalized to total protein. Val-
ues from four independent experiments carried out in triplicate were 
reported as the average fold induction over pcDNA, pRc ± SE: pcDNA, 
pRc (1.00 ± 0.00), Brk (2.92 ± 0.39), and K219M (1.36 ± 0.13); c-
Src, pRc (1.10 ± 0.12), Brk (5.01 ± 0.38), and K219M (1.24 ± 0.18); 
K-Src, pRc (0.99 ± 0.19) and Brk (2.76 ± 0.89). Student's t test was 
used to determine statistical significance between pcDNA pRc and 
pcDNA Brk, between pcDNA pRc and pcDNA K219M, and between 
pRc Brk and c-Src Brk. *P = 0.0027, • P = 0.0322,  P < 0.0086.Page 7 of 10
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strated that Brk mediated phosphorylation of STAT3, but not
of STAT1, STAT2, STAT5, or STAT6 [1]. These studies were
performed in COS1 cells, however, not in breast cancer cells,
and in vitro kinase assays were not performed for STATs other
than STAT3. Using our previously characterized STAT5b-spe-
cific antibodies, we demonstrated here that Brk can also
directly phosphorylate Y699 on STAT5b in breast cancer cell
lines and in an in vitro kinase assay.
Exogenous expression of Brk in the Brk-negative breast can-
cer cell line BT-549 increased endogenous STAT5b transcrip-
tional activity. Interestingly, the catalytically inactive K219M
Brk mutant also significantly increased STAT5b transcriptional
activity compared with vector alone, although not to the extent
seen with wildtype Brk or the constitutively active (Y447F). In
fact, Harvey and Crompton have previously reported that the
kinase-inactive Brk mutant (K219M) could increase the prolif-
eration of T47D cells compared with vector [22]. Since the
K219M mutation disrupts the ATP-binding motif, but not the
Src homology domain 2 or the Src homology domain 3, these
data suggest that Brk has a role in intracellular signaling that
does not require its kinase activity. In these cases, Brk may
function as an adaptor protein. Finally, although the constitu-
tively active Y447F Brk mutant was able to increase STAT5b
transcriptional activity, it was not significantly higher than that
seen with wildtype Brk. This mutation is at the presumptive
autoinhibitory tyrosine phosphorylation site of Brk (Y447),
equivalent to that identified in c-Src (Y527). Although the
Y447F Brk increases phosphorylation of a synthetic peptide,
Figure 6
Breast tumor kinase and signal transducer and activator of transcription 5b roles in DNA synthesist tu or kinase and signal transducer and ac ivator of transcription 5b roles in DNA synthesis. Knockdown of breast tumor kinase (Brk) 
and/or signal transducer and activator of transcription 5b (STAT5b) in SKBr3 cells (a, b) or BT-20 cells (c, d) was performed using the Dharmacon 
siGenome SMARTpool duplex for each protein as per the manufacturer's instructions. (a, c) Seventy-two hours after transfection of the siRNA, cells 
were lysed. Total lysates were analyzed via immunoblotting with anti-STAT5b (top), anti-Brk (middle), or anti-β-actin (bottom) antibodies. (b, d) Sixty-
six hours after transfection of the siRNA, bromodeoxyuridine (BrdU) was added to the medium for 6 hours. The cells were fixed and stained with a 
fluorescent antibody against BrdU. Cells were scored for BrdU incorporation and graphed. Between 160 and 200 cells were counted for each treat-
ment group. (b) Average percentage of BrdU incorporation ± standard error from three independent experiments performed in triplicate for the 
SKBr3 cells: media (21.54 ± 0.16), siLuc (24.98 ± 2.78), siBrk (12.37 ± 1.65), siSTAT5b (12.37 ± 0.51), siBrk/siSTAT5b (12.39 ± 0.21). Stu-
dent's t test was utilized to determine statistical significance between media and siBrk, siSTAT5b, or siBrk/siSTAT5b, and between siLuc and siBrk, 
siSTAT5b, or siBrk/siSTAT5b. *P ≤ 0.0050, • P < 0.0025. (d) Average percentage of BrdU incorporation ± standard error from three independent 
experiments performed in triplicate for the BT-20 cells: media (25.28 ± 0.55), siLuc (26.87 ± 0.52), siBrk (18.97 ± 0.32), siSTAT5b (18.87 ± 0.03), 
siBrk/siSTAT5b (17.37 ± 0.88). Student's t test was utilized to determine statistical significance between media and siBrk, siSTAT5b, or siBrk/
siSTAT5b, and between siLuc and siBrk, siSTAT5b, or siBrk/siSTAT5b. *P ≤ 0.0016, • P < 0.0007.Page 8 of 10
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Available online http://breast-cancer-research.com/content/9/6/R79the autophosphorylation of the activating tyrosine in Brk
(Y342) is comparable with that seen with wildtype Brk
[17,36]. Nevertheless, the Y447F Brk mutant has decreased
transforming potential when compared with wildtype Brk in
NIH3T3 cells [20]. Together, these data as well as the results
we have presented here suggest that the regulation of Brk is
more complex than originally thought, and probably involves its
role as a kinase and an adaptor protein depending on the cell
context.
Since both c-Src and Brk tyrosine kinases are frequently over-
expressed in breast cancer and since they both mediate Y699
phosphorylation of STAT5b, there is potential for these
kinases to either substitute for one another or work together to
activate STAT5b. As shown in Figure 5b, exogenous overex-
pression of c-Src, unlike Brk, did not enhance STAT5b tran-
scriptional activity in the BT-549 cells, although we have
reported that it does in other cell lines [12]. Exogenous expres-
sion of c-Src along with Brk, however, enhanced STAT5b tran-
scriptional activity to a level greater than that with Brk alone.
As the kinase-inactive c-Src did not enhance Brk-mediated
STAT5b transcriptional activity, c-Src kinase activity may play
a role in increasing the phosphorylation and functional activa-
tion of Brk. Together, these results demonstrate that c-Src and
Brk do not merely substitute for one another in mediating
STAT5b transcriptional activation. Rather, Brk can function
independently of c-Src, or these two kinases can work
together to enhance STAT5b activity.
While Brk is not expressed in normal mammary epithelial cells,
it is expressed in 60% of breast tumors – suggesting that Brk
expression is regulated at the transcriptional level in breast
cancer cells [16]. Furthermore, the DNA sequence of Brk iso-
lated from gastrointestinal epithelial cells and that of Brk iso-
lated from breast tumor cells are identical, suggesting that
activating mutations in Brk are not accountable for Brk activity
in breast cancer [18]. Located within the minimal functional
promoter of Brk are NF-κB, Sp1, and STAT consensus bind-
ing sites, all known to play a role in tumorigenesis. Only NF-κB
and Sp1, however, have thus far been shown to bind the Brk
promoter [37]. Reports in human breast cancer samples have
varied, showing that Brk correlates with HER2 and HER4
overexpression, as well as with estrogen receptor positivity
[38-40]. There is also conflicting evidence showing a strong
correlation between Brk staining by immunohistochemistry
and tumor grade in one report [29], and another correlating
Brk expression with long-term survival [39].
Our mRNA and protein analysis across a panel of human
breast cancer cell lines showed no correlation of Brk expres-
sion with estrogen receptor status or EGFR/HER2 overex-
pression (Figure 4). We have, however, shown that
knockdown of Brk significantly decreased DNA synthesis in
the EGFR-overexpressing and c-Src-overexpressing breast
cancer cell lines, SKBr3 and BT-20 (Figure 6). The effect of
Brk knockdown on inhibiting basal DNA synthesis was compa-
rable with that seen with STAT5b knockdown in both cell lines.
Furthermore, simultaneous knockdown of both Brk and
STAT5b had the same effect on decreasing DNA synthesis as
their individual knockdowns, suggesting that this kinase and
substrate converge upon a pathway ultimately leading to pro-
liferation. Ostander and colleagues have shown that Brk
knockdown decreases cell growth as well as epidermal
growth factor-induced (or heregulin-induced) migration of
breast cancer cells [29]. Additionally, knockdown of Brk
decreases epidermal growth factor-induced (or heregulin-
induced) cyclin D1 expression in breast cancer cells [29]. As
STAT5b is known to regulate cyclin D1 through consensus
sites in the promoter, this pathway may be one mechanism by
which Brk and STAT5b together regulate increases in DNA
synthesis. Given the evidence that we have provided for the
functionally relevant regulation of STAT5b by Brk, further pur-
suing the role of this Brk–STAT5b pathway in breast cancer
may provide important novel therapeutic targets.
Conclusion
We have demonstrated that the nonreceptor tyrosine kinase
Brk positively regulates STAT5b activity leading to prolifera-
tion of breast cancer cells. Based on our studies, we propose
that HER2, EGFR, c-Src, and Brk all signal downstream to
STAT5b to increase proliferation of breast cancer cells. We
hypothesize that inhibition of STAT5b would obstruct the pro-
liferative signal that is transmitted via these kinases resulting in
decreased tumor growth.
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